PROM1 and neoplasm: Preclinical study demonstrated that CAR-NK cells targeting specific antigens linked to CSCs (e.g., GD2, EGFRvIII, ErbB2, CD133, PSCA) displayed superior anti-tumor activity compared to parallel-unmodified NK cells.